Novo Nordisk says Hims & Hers' drugs breach its patent; Hims & Hers calls the lawsuit a "blatant attack".
Researchers found that pairing the antibiotic rifampicin with a second compound turned multidrug resistance into a weakness—providing proof of concept for using basic science to design life-saving ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results